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and Hans Scholz, MD, Berlin, Germany
Objectives: In this report we present a novel procedure that uses an arterioarterial prosthetic loop (AAPL) with the
proximal axillary or the femoral artery as a vascular access for hemodialysis in patients who have inadequate vascular
conditions for creating an arteriovenous fistula or graft.
Methods: Between April 1996 and September 2004, 34 patients received 36 AAPLs as vascular access, either as an axillary
chest loop (n 31) or as a femoral loop (n 5). In this procedure the artery is ligated between the anastomoses to direct
flow through the AAPL. Data from all patients undergoing the procedure were prospectively collected.
Results: The indication for an AAPL was the unsuitability of large deep veins in 64%, steal syndrome in 11%, the
combination of only a suitable femoral vein and severe peripheral arterial disease in 22%, and congestive heart failure in
3%. All AAPLs were cannulated 18  4 days postoperatively. Mean follow-up was 31 months (range, 1 to 83). Primary
patency was 73% and secondary patency was 96% at 1 year; these rates at 3 years were 54% and 87%, respectively. The rate
of all interventions for the maintenance of AAPL function was 0.47 procedures per patient year. Four grafts were
abandoned. More than 11,000 hemodialyses with proven efficiency were performed.
Conclusions: The AAPL is an unusual but useful and easy-to-perform alternative procedure to create vascular access for
hemodialysis. It can provide survival for strictly selected patients in whom conventional vascular access is not possible.
The axillary chest AAPL is preferred. (J Vasc Surg 2005;41:1007-12.)Vascular access failure causes substantial morbidity in
patients with end-stage renal disease who require long-term
hemodialysis.1 As standard vascular access, an arterio-
venous (AV) fistula created with a superficial vein or a
prosthetic AV access with a suitable deep vein are used.2
Still, in some patients, veins can be exhausted owing to
multiple long-term indwelling central vein catheters
(CVC), transvenous pacemakers, or previously failed AV
vascular access attempts.2-6
Stenosis and occlusion of central veins can be treated
surgically or by angioplasty to establish sufficient outflow
required for AV access. Central subclavian vein obstruction
can be reconstructed by different surgical techniques with
good results.3,7-11 However, these procedures need a suit-
able jugular vein or undisturbed contralateral venous out-
flow.
Endovascular interventions for the treatment of central
venous obstruction show excellent initial success, but pri-
mary patency rates for 1 year are50%, restenosis rates are
high, and long-term results are uncertain.3,4,11-15 Several
uncommon procedures for maintenance of AV grafts at
central venous obstruction have been published.16-23
However, some of these approaches appear inadequate for
the creation of vascular access.
Symptomatic ischemia distal to an AV fistula occurs in
around 4% of patients.24 In a very few patients, the arterial
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doi:10.1016/j.jvs.2005.02.043status does not allow the construction of an AV graft, even
if the graft is fed by a central artery.
These patients represent a group with complex vascular
access problems that preclude the creation of a conven-
tional vascular access. Tunneled central venous catheters do
not represent an acceptable long-term alternative.2
We developed a procedure to establish an arterioarterial
prosthetic loop (AAPL) for such patients. The AAPL is a
polytetrafluoroethylene (PTFE) graft loop interposed in
the continuity of the axillary or femoral artery that can be
used as the vascular access for hemodialysis.
METHODS
Patients. From April 1996 to September 2004, 36
AAPL procedures for vascular access were performed in 34
patients with end-stage renal disease. All patients who
received an AAPL agreed to the procedure by signing a
consent form.
Indication. An AAPL for vascular access is indicated
only for patients who have no suitable superficial vein
(defined as the cephalic and basilic veins) for an AV fistula
and who belong to one of the following indication groups:
1. The unsuitability of large deep veins (defined as the
subclavian, internal jugular, and external iliac and fem-
oral veins), the unsuitability of all six veins, or the
unsuitability of five of six veins in younger patients with
good prognosis. The last suitable vein should be re-
served as an access for a CVC in an emergency. A vein is
considered unsuitable if an occlusion or high-grade long
stenosis (70% in diameter,4 cm long) of the vein or
the venous outflow is detected and can not be treated
promisingly by any interventions.
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site of an intended AV access or severe access-related
ischemia of an existing AV access without other options
of reconstruction.
3. Cardiac insufficiency that is intolerable to the additional
cardiac load of a high-flow AV graft and the risk of
exacerbation of congestive heart failure.
Operative technique. The central axillary artery for
axillary chest AAPL, or common femoral artery for femoral
inguinal AAPL, were used as vessels for this procedure (Figs
1, 2 and 3). The operative procedure includes the exposure
of the central axillary artery or the common femoral artery,
the subcutaneous placement of an expanded PTFE pros-
thesis (Bard Peripheral Vascular, Tempe, Ariz) with a 6- or
7-mm diameter (adapted to the diameter of the artery) as
the loop; the occlusion and oblique discission of the artery;
and the creation of an end-to-end anastomoses between the
ends of prosthesis and the artery using a 6-0 polypropylene
suture. The length of the implanted graft was 27 to 38 cm.
Management. Duplex mapping of veins and supple-
mentary contrast venography are essential for defining ad-
equacy or inadequacy of deep veins and were performed in
all patients. Color duplex ultrasound scanning of arteries
was regarded as mandatory for all patients. An arteriogra-
phy was performed in all cases of suspected arterial inflow or
outflow lesions (n  9).
After the perioperative administration of heparin, pa-
Fig 1. Axillary chest arterioarterial prosthetic loop.tients received oral anticoagulation (Cumarine), with aninternational normalized ratio of 2.5 to 3.0. Six patients
with a contraindication for oral anticoagulation received
aspirin only (300 mg/day). Patients were hospitalized 7
days. The first needle puncture of the graft was done not
before 2 weeks after the procedure.
The patients’ nephrologists were informed about the
specifics of this access. They were advised to compress the
puncture site for 20 minutes after the removal of the
needle, to adjust the temperature of the reinfused blood, to
continue the supply of heparin until 30 minutes before
finishing hemodialysis, and to refrain from any infusion of
medications (intra-arterial injection).
Every 6 months, patients were followed up in our
institution, where a clinical examination and duplex ultra-
sound scanning of the AAPL were performed, including
measurement of access flow by the Doppler method. Most
patients had one hemodialysis treatment that was used to
determine the Kt/V (clearance multiplied by time/volume
of fluid cleared) and the urea reduction ratio. The Kt/Vwas
determined by using a Hospal urea monitor (DQM 200,
Gambro Hospal GmbH, Martinsried, Germany).
Statistical analysis. The Kaplan-Meier method was
used to compute survival and graft patency. The Cox-
Mantel log-rank test was used to compare the differences
between the Kaplan-Meier method curves. Significance was
assumed at P  .05. Values are expressed as mean  SE or
Fig 2. Femoral inguinal arterioarterial prosthetic loop.observed range.
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In the past 8 years, 36 AAPL have been created in 34
patients. This represents 1.2% of all created vascular ac-
cesses for hemodialysis in our institution during this period.
Themean patient age was 62 13 years; 59% were women.
Comorbid conditions included diabetes mellitus (56%),
peripheral arterial disease (Fontaine stage III and IV) (50
%), coronary artery disease (58%), adipositas (39%), hyper-
lipidemia (53%), and documented hypercoagulability
(19%). The patients had been receiving hemodialysis for
5.4 6.2 years (range, 1 to 30). They had undergone 15
8 (range, 2 to 30) previous procedures for 5  2 (range,
1 to 9) different permanent hemodialysis accesses.
The patients were dialyzed through a temporary CVC
placed in the jugular vein (36%), femoral vein (56%), left
atrium (5%), or through an insufficient AV graft (3%).
AAPL was reserved only for selected cases in which the
possibility for the construction of a conventional access was
precluded. None of the patients had suitable superficial
veins for the creation of a native AV fistula. AAPL place-
ment was indicated in 23 patients (64%) who had unsuit-
able large deep veins. Phlebography demonstrated an oc-
clusion of all six large deep veins in eight patients and a
stenosis of the last patent deep vein in three patients. In 12
patients, one suitable vein (jugular or femoral vein) was
found, where a CVC was placed. A previous endovascular
intervention of stenoses of the subclavian or the innominate
vein had been performed in 10 patients.
In four patients (11%), deep veins were suitable, but all
patients had a severe steal syndrome, with finger necrosis at
a low-flow central AV graft (axillary-axillary chest loop and
Fig 3. Postoperative arteriogram of axillary chest arterioarterial
prosthetic loop 2 years after placement.femoral-femoral looped inguinal access, respectively). Thenecrosis healed after the construction of the AAPL and the
ligation of the AV access. One patient with gangrene re-
quired a finger amputation.
Eight patients (22%) had a mixed indication, with
unsuitable upper body veins and suitable femoral veins, but
coexistent peripheral arterial disease at Fontaine stage IV
(previous major amputation in 5 patients). Severe conges-
tive heart failure (NYHA class IV, ejection fraction 20%,
valvular defects, massive obesity) was regarded as indication
for an AAPL placement in one patient (3%).
In seven patients, the construction of AAPL was per-
formed under local anesthesia and under general anesthesia
in 29 patients. The axillary chest position was preferred in
31 patients (86%), and the femoral artery was used in only
five patients.
No complications were observed in the early postoper-
ative course. All AAPL were cannulated 18  4 days
postoperatively.
During the late postoperative period, thrombosis of the
AAPL occurred in 15 patients (42%) at a mean of 15  14
months (range, 1 to 48) after placement. In nine patients,
repeated thrombectomies were required. Thrombectomy
was combined with the reconstruction of an anastomotic
stenosis in seven patients. A distal embolism of the brachial
artery due to partial thrombus occurred in one patient after
thrombectomy of an axillary AAPL and was treated by
embolectomy. Thrombosis of the femoral AAPL required
immediate thrombectomy, whereas occlusion of the axil-
lary AAPL caused only mild ischemia and was tolerated
much better.
Four AAPL were abandoned. One axillary AAPL
thrombosed repeatedly due to the long stenosis of the distal
axillary artery, and a new femoral AAPL was constructed 19
months after placement. The femoral AAPL in another
patient was destroyed by puncture when it demonstrated
anastomotic stenosis and a new AAPL was placed at the
same site after 48 months. Repeated thrombosis of AAPL
occurred in two patients. In these cases, femoral AV grafts
with only the suitable femoral vein were created 12 and 25
months after AAPL placement, despite a high risk of infec-
tion due to a rectovaginal fistula in one patient. Artery
reconstruction was not necessary in the patients whose
axillary AAPL were abandoned.
The achieved primary and secondary patency was 73%
and 96% at 1 year and 54% and 87% at 3 years, respectively
(Fig 4).
Our analyses revealed only documented hypercoagula-
bility as a risk factor for graft thrombosis (primary patency
rate 80% vs 57% at 1 year and 57% vs 14% at 3 years; P 
.05). A significant difference in patency rates could not be
demonstrated for the site of the AAPL, postoperative anti-
coagulation, diabetes mellitus, peripheral arterial disease, or
gender.
The cumulative survival rate for all patients was 93% at
1 year and 67% at 3 years. No deaths were related to the
AAPL.
Despite instructions provided to the nephrologists, the
needle puncture was performed in only two small areas in
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aneurysms in six patients. Ten reconstructions by replace-
ment of the destroyed graft part were performed in six
patients at a mean of 18 months after placement. In one
patient, an infection at the puncture site was reconstructed
in the same manner after 23 months. The rate of all
interventions for maintenance of AAPL function was 0.47
procedures per patient year.
Postoperative flow of 272  61 mL/min for axillary
AAPL and 416  40 mL/min for femoral AAPL was
measured by a duplex scan. The flow changed only margin-
ally over time.
More than 11,000 hemodialysis treatments were per-
formed in patients through the AAPL. A two-needle punc-
ture was the standard technique. All but two AAPLs al-
lowed an efficient hemodialysis in the regular time of a
4-hour treatment at a dialysate flow rate of 284  53
mL/min, arterial pressure of 65  28 mm Hg, and
outflow pressure of 173  39 mm Hg. In 90 measure-
ments, the urea reduction ratio was 71%  9%. The Kt/V
exceeded 1.2 (range, 1.2 to 1.8) in 4 hours of therapy at a
dialyzer blood flow rate of 200 mL/min for 72 measure-
ments in 22 patients. For two patients with a dry weight
100 kg, the Kt/V was between 0.9 and 1.1. The treat-
ment time for these patients was extended to 5 hours.
A compression time of 10minutes was sufficient to stop
the bleeding at the puncture site in most of the patients.
Hemodialysis was well tolerated by the patients. A painful
reaction by distal arteries to the reinfused blood was ob-
served in a few cases of high-flow dialysis (400 mL/min).
In no patient with existing angiopathy or congestive
heart failure was a deterioration of the symptoms observed.
Finally, we present a special case of AAPL. One very
slim patient with a left-sided subclavian AAPL, which had
been performed earlier in another hospital, was referred to
our center because of insufficient hemodialysis due to a
graft flow140 mL/min. After the exclusion of an arterial
Fig 4. Curves calculated by the Kaplan-Meier method for pri-
mary and secondary patency and their negative standard error bars.stenosis as the reason for the low flow, a second subclavianAAPLwas constructed at the right side with a postoperative
flow of 160 mL/min. One AAPL was used as an artery, the
other as the efferent vessel. A sufficient hemodialysis with-
out any problems over 26 months at a dialysate flow of 250
mL/min was possible because of nonexistent recirculation.
DISCUSSION
The use of an artery as permanent vascular access for
hemodialysis is not a new procedure. Brittinger et al25 used
the subcutaneously fixed superficial femoral artery for nee-
dle puncture. However, in our opinion, this is a very
traumatic procedure that can be performed only in younger
individuals with an unchanged artery. Also, the recurrent
cannulation of the artery can lead to substantial complica-
tions (stenosis, thrombosis, arterial aneurysms) that require
extensive surgery.
Butt and Kountz26 reported satisfactory results with an
arterial femoropopliteal graft that used a bovine carotid
artery as vascular access in seven patients. Similar tech-
niques were reported by Zingraff et al27 and Giacchino et
al.28 In contrast to these procedures that use a bypass for a
patent artery, AAPL represents the subcutaneous place-
ment of an artery that is elongated by graft interposition.
As a result of these promising initial results,29 we per-
formed 36 AAPL in 34 patients over an 8-year period.
The basics of the AAPL compared with an AV graft are:
1. A vein is not essential.
2. The distal perfusion is not decreased.
3. The cardiac load is not increased.
Among the potential problems of AAPL as an angioac-
cess, we considered the following as most relevant:
1. Occlusion of the graft may lead to distal ischemia and
requires immediate salvage. It was observed that throm-
bosis of axillary AAPL was well tolerated. In the cases of
an abandoned axillary AAPL, the arterial reconstruction
was not necessary because of good collateralization. The
thrombosis of a femoral AAPL required immediate
thrombectomy, however.
2. If the whole graft becomes infected, it is mandatory to
remove the graft and reconstruct the artery. A severe
infection was not seen. However, as a precaution, we
recommend that the artery be mobilized over a longer
distance than necessary for clamping during the con-
struction of AAPL. A situs will be achieved that renders
the potential reconstruction easier.
3. Hemodialysis through an AAPL may cause different
potential problems such as embolism, the formation of
an aneurysm, and painful reperfusion.30 Embolism was
observed in only one patient and does not pose a sub-
stantial problem. Because the intraluminal pressure of
the AAPL is arterial, it is much higher than the pressure
of a well-working AV graft. The risk that the APPL will
develop a false aneurysm at puncture sites is therefore
increased but is easy to manage. In fact, false aneurysms
can be prevented if a careful puncture technique is
applied.
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blood flow rate of above 400 mL/min. This effect seems to
be caused by the reaction of the arterial wall to higher
pressure.
Unsuitability of the large deep veins was the indication
for AAPL in 64% of the patients. In an additional 22%,
upper body veins were inadequate and both femoral veins
were patent; however, these patients had severe peripheral
arterial disease. The placement of a femoral AV graft would
have certainly led to steal syndrome, with the deterioration
of signs and the threat of amputation. Our experience with
axillofemoral AV graft31 in two patients was unfavorable.
Severe steal syndrome at a central AV graft was the
indication for AAPL procedure in four patients. A flow
600 mL/min, despite normal arterial inflow, precluded
the possibility of reconstruction of steal syndrome. The
distal revascularization interval-ligation procedure was not
considered as an option for reconstruction because the
femoral or central axillary veins were the only adequate
veins for AV access in these patients.
For one patient, severe cardiac insufficiency was seen as
an indication for AAPL. This is a very rare indication and
may be a difficult decision in the view of life expectancy.
This patient died only 2 months after placement of AAPL
because of the sudden deterioration of cardiac function
after previous stabilization.
The patency and intervention rate of 0.47 procedures
per patient year are comparable with results of AV grafts
and meet the demands of the National Kidney Foundation
Dialysis Outcomes and Quality Initiative (DOQI) Guide-
lines.2 A secondary patency rate of 87% at 3 years is encour-
aging with regard to the poor vascular conditions and the
missing alternative for vascular access.
The patency rate was influenced by a high mortality
rate; however, this is a general problem of vascular access
surgery.32 The patients who received AAPL represent a
worst selection. Nevertheless, even in retrospect, in only
three patients did we consider that CVC might have been
an alternative access.
Most patients had a history of multiple failed vascular
accesses and several vein occlusions after temporary CVC
placement. An increased risk of thrombosis of the AAPL
was assumed, and postoperative oral anticoagulation was
routinely applied. Nevertheless, no difference in patency
compared to that of patients who received aspirin alone was
observed.
It is important to consider the lower flow of the AAPL
compared to the flow of AV grafts. DOQI guidelines
demand a flow of 600 mL/min as a minimum for AV
grafts.2 This limit is justified by observed patency rates. The
observed patency of AAPL is much better than that for AV
grafts with the same flow, presumably because of the quite
different flow characteristics (pulsatile arterial flow with a
high systolic flow component).
The desired sufficient extracorporeal blood flow of 300
mL/min2 was reached. Long-term hemodialyses verify the
usefulness of AAPL as also indicated by the efficient urea
reduction rate and acceptable Kt/V. The AAPL is notrecommended for a dialysate blood flow rate 350 to 400
mL/min because high flow is accompanied with higher
rates of recirculation and possible painful reperfusion.
The axillary AAPL was preferred to femoral AAPL,
even though an equivalent patency was observed. This
preference is based on a muchmore tolerable malperfusion,
mostly without any significant signs, in the case of throm-
bosis of axillary AAPL. The increased comfort for the
patients and the lower risk of infection are additional argu-
ments in favor of the axillary AAPL.33
A close cooperation with nephrologists and their infor-
mation about the special characteristics of AAPL is essen-
tial. The AAPL has to be regarded as an artery. In particular,
careful digital compression of the puncture sites after nee-
dles are removed and the schematized change of the punc-
ture sites must be accepted.
Despite the promising results presented here, the indi-
cations for AAPL should be defined rigidly. This procedure
was performed on 34 patients during an 8-year period.
Within this period, nearly 4,000 accesses for dialysis were
constructed, and most patients had previously undergone
procedures for vascular access.
The AAPL is reserved only for patients without any
other promising possibility for the creation of a more
conventional vascular access. For these strictly selected
cases, this approach is an unusual but very efficient and
attractive alternative as a vascular access for hemodialysis
and can sustain the survival of patients.
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